Lundgren S, Søreide J A, Lea O A
Department of Oncology, University of Bergen, Norway.
Anticancer Res. 1994 May-Jun;14(3B):1313-6.
A possible influence of tamoxifen (TAM) treatment on the measurable content of some steroid hormone receptors (i.e. ER, PgR, AR) from primary breast cancers has been evaluated. In eleven postmenopausal women, two biopsies were taken from the same tumor, the first biopsy before starting endocrine treatment, and a second biopsy after 8 weeks on tamoxifen treatment. A significant decrease in ER content was found both using a ligand binding (p < 0.005) and an enzyme immunoassay (p < 0.02). As for the PgR and AR content, no significant changes in the mean content were found.
已评估他莫昔芬（TAM）治疗对原发性乳腺癌某些类固醇激素受体（即雌激素受体、孕激素受体、雄激素受体）可测量含量的可能影响。在11名绝经后女性中，从同一肿瘤取了两次活检样本，第一次活检在开始内分泌治疗前，第二次活检在他莫昔芬治疗8周后。使用配体结合法（p < 0.005）和酶免疫分析法（p < 0.02）均发现雌激素受体含量显著降低。至于孕激素受体和雄激素受体含量，平均含量未发现显著变化。
